[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573188":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":38,"collaborators":40,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":7,"enrollmentInfo":54,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"iOMEDICO AG","INDUSTRY",null,[9],{"name":10,"affiliation":11,"role":12},"Eyck von der Heyde, Dr.","Onkologische Schwerpunktpraxis","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Laura Serrer","CONTACT","+49 761 15242-0","rope@iomedico.com",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Onkologisches Studienzentrum Dr. med. Ingo Zander & Dr. med. Eyck von der Heyde","RECRUITING","Hanover","Lower Saxony","30161","Germany","DE",{"type":29,"coordinates":30},"Point",[31,32],9.73322,52.37052,{"lat":32,"lon":31},[35],{"name":10,"role":16,"phone":36,"phoneExt":7,"email":37},"+49511311660","vdheyde@onkologie-am-raschplatz.de",{"type":39,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[41],{"name":42,"class":43},"AOP Orphan Pharmaceuticals Germany GmbH","UNKNOWN","100573188","ropeginterferon-alfa-2b-in-patients-with-polycythemia-vera-pv-without-symptomatic-splenomegaly-100573188",false,"NCT06743035","Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly","Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly: A Prospective, Longitudinal, Multicenter, Observational Study in Germany","ROPE","Inclusion Criteria:\n\n* Age ≥18 years\n* Confirmed diagnosis of PV without symptomatic splenomegaly\n* Indication and decision for treatment with ropeginterferon alfa-2b in accordance with current SmPC\n* No prior treatment with ropeginterferon alfa-2b (Patients are allowed to be enrolled up to 6 weeks after their first dose of ropeginterferon alfa-2b but must still be on treatment at the time of enrollment.)\n* Dated signature of informed consent form\n* Participation in Patient-Reported Outcome (PRO) assessment in German language and completion of questionnaire at time of study enrollment\n* Other criteria according to current Summary of Product Characteristics\n\nExclusion Criteria:\n\n* Participation in an interventional clinical trial (except follow-up)\n* Other contraindications according to current Summary of Product Characteristics","ALL","18 Years",{"count":55,"type":56},200,"ESTIMATED","OBSERVATIONAL","The primary objective of this non interventional study is to evaluate symptom burden in adult patients with PV without symptomatic splenomegaly during treatment with ropeginterferon alfa-2b in a real-world setting. Further patient-relevant endpoints include effectiveness including complete hematologic response (CHR), event-free survival (EFS), safety and tolerability, treatment reality including dosing details as well as factors affecting treatment decision making.",[60],"Polycythemia Vera",[62,63,64,65],"Ropeginterferon alfa-2b","polycythemia vera","symptom burden","myeloproliferative neoplasm","2026-01-08",{"date":68,"type":69},"2026-01-09","ACTUAL",{"date":71,"type":69},"2024-12-03",{"date":73,"type":56},"2029-07",{"name":5,"class":6},1]